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system distinguishes itself from the other methods in that the interaction between a small molecule and a 20 Fraunhoferstrasse Planegg/Martinsried 82152 target protein occurs in intact cells rather than in vitro. Y3H is based on the yeast two-hybrid system (Y2H), Germany 2 GPC Biotech Inc.
which has proven to be a powerful tool for detecting protein-protein interactions [5] [6] [7] . Adaptation of Y2H to 610 Lincoln Street Waltham, Massachusetts 02451 Y3H required the use of small molecule hybrid ligands, sometimes also referred to as chemical inducers of dimerization (CIDs) or "dimerizers" [8] . CIDs have been widely used to crosslink ("dimerize") at will proteins in Summary living cells that have been engineered to express hybrid proteins with appropriate ligand binding and signaling In this study, we explored the application of a yeast three-hybrid (Y3H)-based compound/protein display domains (three-hybrid systems). In this manner, numerous biological processes, such as activation of specific system to scanning the proteome for targets of kinase inhibitors. Various known cyclin-dependent kinase signaling pathways, protein subcellular localization, or gene expression, were placed under the control of (CDK) inhibitors, including purine and indenopyrazole analogs, were displayed in the form of methotrexate-chemical dimerizers [8] [9] [10] . In contrast, small molecule hybrid ligands can be used in Y3H to identify and charac-based hybrid ligands and deployed in cDNA library or yeast cell array-based screening formats. For all terize small molecule-protein interactions. Liu and colleagues first described the Y3H system inhibitors, known cell cycle CDKs as well as novel candidate CDK-like and/or CDK-unrelated kinase tar-and its application to screening of cDNA libraries for target discovery [1]. An engineered glucocorticoid re-gets could be identified, many of which were independently confirmed using secondary enzyme assays and ceptor (GR) protein was used as a DNA-bound docking platform to display a dexamethasone (DEX)-tethered affinity chromatography. The Y3H system described here may prove generally useful in the discovery of FK506 hybrid ligand to target proteins that could activate reporter gene expression upon binding. FKBP12, candidate drug targets. a known target of FK506, was identified, indicating that Y3H could be a valuable tool for the identification of Introduction novel small molecule-protein interactions, at least in principle. Despite this first promising report on Y3H and Organic small molecules have been widely used as cell permeable ligands to elucidate mechanisms of signal the broad uses of Y2H for mapping protein-protein interactions, only very few studies have subsequently made transduction and as therapeutic agents. The majority of small molecule drugs elicit their pharmacological action use of Y3H for the characterization of small moleculeprotein interactions [11] [12] [13] [14] . Only one other study made through binding to protein targets. The identification of such targets is of fundamental importance to our use of Y3H in screening cDNA libraries for target identification [14], reporting the successful identification ("reunderstanding of the molecular basis of drug action discovery") of dihydrofolate reductase (DHFR) as a tarand of mechanisms underlying drug efficacy and side get of methotrexate (MTX) when using MTX as the "bait" effects. tethered to DEX. Whether Y3H is suitable for the detec-Traditionally, the identification of receptors for small tion of weaker and novel interactions (FK506 and MTX molecules has relied on in vitro biochemical methods, display affinities for FKBP12 and DHFR in the nanomolar such as photo-crosslinking, radiolabeled ligand binding, to picomolar range, respectively) and is amenable to and affinity chromatography. Recent technological adhybrid ligands incorporating different types of organic vances in protein separation and analytical methods small molecules, e.g., enzyme inhibitors, remained unhave significantly improved affinity chromatographyclear. based approaches for the detection of small molecule-In the present study, we set out to explore in more protein interactions. However, these approaches remain detail the potential and limitations of Y3H for the identification of novel small molecule protein targets, with em- . Thus, methods that would support the protein consisting of a transcriptional activation domain identification of the target spectrum of kinase inhibitors (AD) derived from the yeast transcription factor GAL4 could have an impact on drug discovery across diverse fused to a polypeptide (Y) potentially capable of binding therapeutic areas. Here, we describe the successful imto the test compound of interest. Compound-mediated plementation of versatile screening approaches with a recruitment of the AD-fusion protein to the proximity Y3H system that employs MTX-based hybrid ligands of the promoter region of an integrated reporter gene and the identification of novel candidate targets for variinduces reporter gene expression. In this study, we reous widely used cyclin-dependent kinase inhibitors with lied mostly on the use of a reporter gene encoding HIS3, antitumor activity.
an auxotrophic marker widely used in various Y2H systems. Expression of HIS3 enables yeast cells to grow in the absence of histidine in the culture medium,
Results
allowing for easy and sensitive detection of a hybrid ligand-induced interaction event. The Y3H Assay System Figure 1B shows an example of the synthesis of a Figure 1A highlights the three major components of the kinase inhibitor MFC used in this study, GPC286076 Y3H system used in this study. (1) A hybrid ligand, here (purvalanol B-MFC). We found that use of a PEG-spacer named methotrexate fusion compound (MFC), which is yielded MFCs with good water solubility properties. This composed of a methotrexate "anchor" moiety coupled to a small molecule test compound (SM) of interest via a facilitates an even diffusion of compound through agar and more uniform and robust growth of affected yeast hybrid ligand GPC285937 (a DEX-MFC) and MTX-5PEG-OCH 3 , a "universal control" compound that contains clones. PEG-spacers containing three or more ethyleneglycol subunits were found necessary for good per-methotrexate and PEG moieties but lacks a test compound ( Figure 2A ). All MFCs derived from the CDK inhibi-formance in Y3H (data not shown). Test experiments using the DEX-derived MFC, GPC285937 (Figure 2A For the design of the purvalanol B-MFC, GPC286076 compounds (we refer to this as yeast halo-analysis). In addition, kinase clones that were otherwise indepen- (Figure 2A ), a suitable attachment site for the spacer was derived from the CDK2-purvalanol B crystal structure, dently cloned or identified in Y3H screens with compounds other than purvalanol B were used to generate which suggested that attachment to the carboxylic acid of the 6-anilino substituent of the inhibitor would not recombinant yeast strains that were included in the replica spotting of arrays. As discussed below, analysis interfere with its interaction with the kinase [16, 20, 30]. and 4 ). Interestingly, a weak but significant signal was more, most of the kinases did not score positively with the MFC of the methylated, CDK-inactive form of purva-observed consistently also with CDK4, which is inhibited by purvalanol B in vitro at micromolar IC 50 (see Figure  lanol B (Me-purvalanol B, GPC286207 ). Those kinases that did score positively, i.e., CSNK1, CLK1, PAK4, and 2A). The 15 additional novel interaction events (excluding CDK4) included several additional CDC/CDK-related PKWA, appeared to have a significantly lower apparent affinity for Me-purvalanol B as compared to purvalanol kinases (CDK3, CDK9, CCRK, CLK4, PCTK3), other types of serine/threonine kinases (GSK3A, PKWA, B, as suggested by the significantly lower halo-signal intensity observed at the high dose of compound and CSNK2A2, AKT1, MSK1, PRKCG, CAMK2A, SNRK), one the complete lack of signal at the lower dose of compound (see Figure 4 for overall scores). In summary, the results presented in Figure 4 reveal a broad spectrum of candidate targets for purvalanol B and indicate that overlapping structural requirements dictate the interaction of the CDK-active form of purvalanol B with its known and newly identified candidate interactors.
As a control, we synthesized a CDK-inactive N6-methyl-of such an extended array led to the identification of additional candidate purvalanol B binders and facilitated ated purvalanol B (Me-Purvalanol B)-MFC, GPC286207 (Figure 2A). Replacement of the N6 hydrogen, which a more thorough comparative analysis using a diverse set of MFCs derived from other kinase inhibitors. Interro-forms a key hydrogen bond with Leu83 of CDK2, with a methyl group was shown to greatly reduce the CDK-gation of replica arrays was performed at a high and low dose of MFCs. Spotting of a high amount of compound inhibitory activity of purvalanol B as well as its ability to bind to other kinases [20]. The chemical structures of translated into an estimated concentration of compound in the yeast halo-analysis that is comparable to that the roscovitine-MFC (GPC286077) and the indenopyrazole IP-1-MFC (GPC286026) are also shown in
The target spectrum outlined in Figure 4 included a number of known targets of purvalanol B but not all (i.e., CDK7, ERK1, ERK2). Also, for a few of the known targets, the presumed "interaction strength" (as reflected by the extent of yeast growth/Y3H halo-signal) did not correlate well with the known potency of purvalanol B toward these targets (CDK1, CDK5). This is not surprising, given that a number of factors may govern detection of an interaction event. These include but are not limited to the following factors. will also influence the extent to which targets can be identified. lanol B has higher affinity for CSNK1E and G than roscovitine, at least in the context of Y3H. In contrast, drawing conclusions with respect to potential differ-Comparative Array-Based Y3H Screening with Kinase Inhibitors ences in relative binding affinities of a given compound for one or the other target is more speculative, given As described in the previous section, replica yeast cell array screening can provide a useful approach to target the variables associated with expression, folding, and translocation of fusion proteins in yeast. However, if one profiling and comparative analysis of small molecules. 3B and 4) . Replica arrays including the 38 selected kinases were interrogated with CSNK1D but not CSNK1E, suggesting that CSNK1D could be a higher-affinity target. More studies will be the respective MFCs. Roscovitine-MFC scored positively with its known target CDK2. Interestingly, it also necessary to evaluate the extent to which such correlations can be made with any level of confidence. Like scored positively with CSNK1D and CSNK1E but, in contrast to purvalanol B, not with CSNK1G. Figure 5A shows purvalanol B-MFC, roscovitine-MFC also scored with PCTK1 and comparatively weakly with CLK1, PAK4, that the differential behavior of these closely related purine analogs becomes even more pronounced when GSK3a, PCTK3, and PKWA. Hence, roscovitine-MFC appears to have a more restricted Y3H-target profile than scores at low dose are considered. Purvalanol B-MFC scored positively with all three CK1 isotypes, whereas purvalanol B-MFC. Comparatively, the indenopyrazole IP-1-MFC recognized a broader spectrum of targets. It roscovitine-MFC only scored with CSNK1D. Given that both the purvalanol B and roscovitine MFCs displayed scored positively with its known targets CDK1, CDK2, and CDK4. In addition, the IP-1-MFC interaction profile a comparable "cellular uptake"/DHFR binding competition profile (Figure 2B) , these results suggest that purva-extended to other CDC/CDK-related kinases and other types of serine threonine kinases (Figures 3B and 4) .
Features distinguishing even closely related com-controls for protein expression levels, it may be possible to tentatively rank closely related targets according to pounds can be revealed by this approach. This is further highlighted by the comparative analysis performed with observed "interaction strength." For instance, as shown in Figure 5B, both CSNK1D and CSNK1E seem to MFCs derived from the purine analogs purvalanol B and roscovitine, the indenopyrazole IP1, and derivatives of achieve similar expression levels in yeast. However, at low dose of compound, roscovitine-MFC scored with these compounds (Figures

RSK-3, FYN, YES, and LCK. Enzyme inhibition at 1 M purvalanol B was greater than 50% in each case, sug-These targets have not been described previously for any indenopyrazole. The CDK-inactive IP-1*-MFC did
gesting that IC 50 values for these kinases likely range below 1 M. In summary, with respect to targets identi-not score positively with any of the kinases, except weakly with CLK1, indicating that overlapping structural fied in cDNA library screens, 12 of 16 novel candidate targets scored positively in at least one secondary requirements dictate interaction of the CDK-active form of IP-1 with its known targets and most of the newly assay. In total, 22 novel interactions were confirmed by at least one secondary assay. identified kinase targets. Thus, as for MFCs of purvalanol B and roscovitine, IP1-MFC appears to have a more extended target profile than one may have anticipated, Discussion especially considering the putative associations with kinases other than cell cycle kinases.
The ease with which recombinant yeast cells can be generated and manipulated in the laboratory has greatly contributed to the success of the development and ap-Biochemical Analysis and Validation of Y3H Interactions plication of yeast two-hybrid systems to mapping of a wide range of different protein-protein interactions on To further scrutinize the extent to which positive Y3H scores are likely to reflect bona fide small molecule-a proteomic scale [7]. In the present study, we explored the potential of a related yeast-based molecular interac-protein interactions, we evaluated the ability of purvalanol B to interact in vitro with targets identified by Y3H. tion system, Y3H [1], for the discovery of novel small molecule-protein interactions and evaluated various A representative sample of interactions was evaluated that included known and novel candidate interactors. screening approaches with MTX-based hybrid ligands incorporating small molecule kinase inhibitors. Both The analysis included the following: (1) in vitro enzyme assays with purified kinases and (2) affinity chromatog-cDNA library and focused screening of yeast cell arrays displaying selected polypeptide ORFs led to the identifi-raphy assays to detect binding of cellular proteins to immobilized purvalanol B (but not Me-purvalanol B). cation of known targets as well as many novel candidate targets. As shown for the purine analog purvalanol B, PEGylated purvalanol B (intermediate A, R ϭ H, Figure 2A) was directly coupled to solid phase, as previously many of the interactions involving putative novel kinase targets could be confirmed by either one or more sec-described [20], incubated with cell extracts, and bound proteins were eluted and subjected to analysis. For the ondary in vitro binding or enzyme inhibition assays, indicating that a significant proportion of interaction events detection of endogenous proteins, cellular extracts derived from Jurkat cells were used. The identity of bound
observed with the Y3H assay system described herein do reflect, or are likely to reflect, bona fide small mole-proteins was determined by either LC-MS analysis (liquid chromatography-mass spectrometry) or immunoblot cule-protein interactions. Based on these findings, we conclude that Y3H is a powerful method for scanning analysis using commercially available "antitarget" antibodies. In a complementary approach, extracts derived of the proteome for candidate small molecule kinase inhibitor targets. from transiently transfected 293 cells were used to detect binding of myc-tagged kinase/kinase domain-Prior to this study, it was unclear whether expression of various kinases would interfere with yeast growth and encoding polypeptides by immunoblot analysis using an anti-myc-tag antibody. thus be incompatible with Y3H. The results we obtained suggest that many different types of kinases can be Figure 6 
shows examples of typical immunoblot experiments. Specific binding to immobilized purvalanol B expressed as fusion proteins in yeast in a form suitable for interaction with small molecule ATP-competitive ac-was detected for a number of endogenous or exogenous kinases, including the novel candidate targets CDK9, tive site kinase inhibitors. Interestingly, in several instances we noticed that in the presence of compound the steady-PCTK1, CLK3, GSK3a, CSNK1D, MSK1, EPHB2, and FLT4 (the approach was also validated by including anal-state levels of kinase fusion proteins increased (data not shown), an effect that is likely to facilitate the detection ysis of known targets, such as CDK1, CDK2, CDK5, CDK7, ERK1, and ERK2). No binding to immobilized of certain interactions. Either full-length open reading frame (ORF) or partial ORF-encoding polypeptides en-Me-purvalanol B or PEG-spacer alone was detected. Expression of some targets was barely or not at all
compassing kinase domains may be suitable or even required for productive interactions to occur in Y3H, detectable (AKT1, CLK1, PKWA, SNRK) and hence failed to be reconfirmed by this approach. As shown in Figure  depending on the type of kinase (e.g., not surprisingly, only the cytoplasmic domains of receptor tyrosine ki-7, several additional Y3H-identified targets were detected by affinity chromatography/LC-MS analysis of nases were identified). Hence, high quality, complex cDNA libraries encoding multiple fusion proteins of Jurkat cell extracts (i.e., detection of endogenous proteins), including the novel candidate targets CDK3, candidate targets are an important factor in Y3H screening, which is reminiscent of the well-established obser- CDK9, CCRK, PCTK2, PCTK3, CSNK1D, CSNK1E,  CSNK2A2, CAMK2G, PAK4, RSK-3, FYN, YES, and LCK vations that complex protein-domain-encoding cDNA libraries are a major contributor to successful Y2H (known targets, e.g., CDK1, CDK5, ERK1, and ERK2, were also identified). No binding to immobilized Me-screening for the detection of protein-protein interactions. purvalanol B was detected for any of the kinases. As also shown in Figure 7 , several novel interactions were Judging from the range of interactions identified in this study, the sensitivity limit of Y3H appears comparable to confirmed using in vitro enzyme assays, including CDK3, 
In vitro binding of cellular proteins from Jurkat cells (endogenous proteins) or 293 cells (exogenous, myc-tagged proteins) to bead-immobilized purvalanol B. Protein binding was detected by immunoblot analysis using antibodies directed against endogenous proteins or the myc-tag of transgene-encoded fusion proteins, as indicated. Immobilized, Me-purvalanol B and PEG-spacer alone served as controls, as indicated.
Very weak or no significant protein expression was detected for AKT1, CLK1, PKWA, and SNRK.
that of Y2H [35] (low-micromolar affinity interaction). For most suitable for a "yes or no" detection of an interaction, with a presumed limit for detection of low-micromo-instance, purvalanol B-MFC detected CDK1, CDK4 and CK1, while roscovitine MFC detected CDK2. Purvalanol lar affinity type of interactions. Thus, although the kinase inhibitor screens performed in this study revealed a B and roscovitine inhibit these enzymes in vitro with IC 50 values in the higher nanomolar to low micromolar range.
number of interesting novel candidate targets, the pharmacological relevance of these interactions remains to Thus, the sensitivity of Y3H ought to be adequate for detection of many molecular interactions of pharmaco-be determined. Ranking such interactions by affinity criteria would provide an important next step and further logical interest. Y3H signal intensity may, however, not adequately reflect differences in relative affinity of a facilitate the prioritization of targets for functional validation. For instance, the question of whether inhibition of small molecule for different targets, given that factors other than ligand-protein affinity may affect readout, certain CK1 subtypes by the purine analogs purvalanol B and roscovitine plays an important role in the antitumor such as protein expression, folding, and nuclear translocation, or positioning of the PEG-spacer/linker on the activity of these compounds (and potentially other purine analogs) warrants further investigation, especially test compound. Thus, Y3H analysis appears generally when considering that R-roscovitine (also known as pounds that would compete for binding to that target, although this type of assay would be more suitable in CYC202) has entered phase I/II human oncology clinical trials as a CDK2 inhibitor [23, 24] . the context of mammalian cells, given the natural permeability barrier displayed by yeast cells to (nonhybrid) Scanning of focused gene/protein families (e.g., kinases) or selected ORF collections may be pursued us-small molecules. A recent, elegant study reported the use of a Y3H-based assay for the identification of pro-ing yeast cell array screening, as exemplified in this study by the kinase array analysis. The array screening teins with chemical bond-cleaving properties [39] , providing an example of application to enzyme catalysis. approaches described in this study made use of 96well array formats, and currently available robotics can
The present study indicates that Y3H can be applied to the discovery of novel candidate drug targets, providing support the analysis of hundreds to thousands of interaction events in a period of a few days. These screening an alternative or complement to current approaches in small molecule mechanism of action studies. formats have therefore the potential to enable rapid comparative screening of small molecules and the characterization of interactions of small molecules with tar-Significance gets for which standard or routine enzyme or biochemical assays are not readily available. Scanning of the The identification of protein targets of organic small molecules is a critical step toward an understanding proteome may be approached using cDNA-library screening. This screening format represents a more ran-of the molecular basis of drug efficacy and side effects. Unfortunately, the identification of such targets re-dom approach to target discovery that may lead to valuable insights into the molecular basis of drug action. mains a current major bottleneck both for drug discovery and chemical genetic studies. We have developed The Y3H system described herein may conceivably also be used to find novel ligands for targets. For instance, a generic Y3H-based compound-protein binding assay and screening approaches that enable the identifica-focused small molecule hybrid ligand libraries could possibly be used to screen for target binding properties tion of targets of small molecules kinase inhibitors, an important class of pharmaceutical agents. The sys-by parallel array profiling of a selected group of candidate targets. Alternatively, a specific hybrid ligand-tar-tematic screening approaches described in this study should be applicable to mechanism of action studies get assay could arguably be used to screen for com- MFC synthesis (e.g., purvalanol B-MFC, GPC286076) each spot, a small aliquot of yeast cells (7 l) was added. Growth are provided in the Supplemental Data (appendix 3). of yeast was determined after an incubation of 3 days at 30ЊC. A genetic counterselection method was used to test the dependence Bacterial and Yeast Strains of the reporter activation on the expression of both fusion proteins.
E. coli strain DH10B (Life Technologies, UK) was used for all bacterial
The plasmid pBYK encodes for the dominant-negative selection work in this study. The Saccharomyces cerevisiae strains used in marker CYH2, enabling active plasmid loss on media containing this study were either L40 (Invitrogen, NL; Mat-␣, his3-⌬200, trp1- cyclohexamide. To test for DHFR-independent activation, all ar- 901, leu2-3,112, ade2, LYS2::(4lexAopHIS3), URA3::(8lexAopLacZ) , rayed yeast colonies were tested for reporter activation in the pres-GAL4) or the derivative strain 6A (GPC Biotech; MATa, his3-⌬200, trp1-901, leu2-3,112, LYS2::(4lexAopHIS3), ade2::(6lexAopURA3) , 1 g/ml cyclohexamide [40] . To test for AD-fusion protein indepen-ura3: :(8lexAopLacZ), GAL4, gal80, can1, cyh2 ). Both strains enable dent activation, a strain expresssing only the pBYK-DHFR fusion the use of a LexA BD-based protein interaction system using the protein was tested with MFC on media lacking tryptophane and HIS3 and/or LacZ reporters and the use of commercial cDNA librarhistidine. ies fused to the GAL4p activation domain. Yeast cells were grown in synthetic dextrose (SD) media with appropriate auxotrophic sup-Plasmid Isolation plements [36] . Standard genetic methods were followed.
ence of MFC on plates lacking leucine and histidine and containing
Plasmids were isolated from yeast cells using the QIAprep96 Turbo Miniprep Kit (Qiagen, NL). Cell material was directly taken from Plasmids selective agar trays, resuspended in buffer 1 supplemented with The E. coli dihydrofolate reductase-encoding gene was amplified zymolyase at a final concentration of ‫4.0ف‬ mg/ml, and incubated using the following primers: DHFR-1 (5Ј-GGGGGTCGACATGATCA at 37ЊC for 60 min. After this preincubation, the manufacturer's GTCTGATTGCGGCGTTAGCG-3Ј) and DHFR-2 (5Ј-GGGGGCGGC protocol was followed. One tenth of the eluted DNA was transformed CGCTTACCGCCGCTCCAGAATCTCAAAG-3Ј), using a genomic bacinto electro-competent E. coli cells using standard procedures. Amterial library (Clonetech, Palo Alto, CA) as a template. The PCR picillin-resistant colonies were selected, amplified, the plasmids product was digested with SalI and NotI and subcloned into pBYK were isolated, and cDNA inserts were sequenced and identified (GPC-Biotech), resulting in the vector pBYK-DHFR encoding a LexA using standard databases and blast algorithms.
(DBD)-DHFR fusion protein. pBYK is a variation of pBTM117c [40], in which a kanamycin-resistance gene replaces the ␤-lactamase
Competition Experiments gene.
The invariable component of all MFCs, the "anchor," is MTX. This shared feature was used to set up competition experiments in yeast cDNA Libraries cells in which competition for binding of a test MFC with a "refer-Strain 6A ϩ pBYK-DHFR was transformed using the lithium acetate ence" MFC to DHFR was determined. IP-1 was used as a reference method [37] with any of the following pACT2-cDNA libraries pur-MFC. A specific protein domain of human BAP28 (Q9H583), which chased from Clontech, Palo Alto, CA.: human brain, liver, heart, was found to bind specifically to IP-1 in the Y3H assay, was used placenta, and testis. Alternatively, oligo-dT primed, directionally as an AD-fusion protein. Interaction induced a strong activation of cloned cDNA libraries (derived from human testis, HeLa and B-cell the HIS3 reporter gene. Competitive binding to DHFR of a test MFC lymphoma line K562 mRNA) were generated via SalI-NotI adaptoris reflected in a reduction of IP-1-MFC-induced reporter activation. based cloning using a Superscript cDNA library construction kit A "growth" dose-response experiment was performed for each test following manufacturer's instructions (Invitrogen). The cDNAs were MFC using serial dilution of the test compounds and a fixed amount subcloned into the SalI-NotI linerazied yeast shuttle vector pUACH. of IP-1-MFC. For each data point, 2 ϫ 10 5 yeast cells expressing pUACH is based on the plasmid pGAD425 [41] with the addition of the DBD-DHFR and the AD-BAP28 fusion proteins were incubated the CYH2 expression cassette which confers sensitivity to cyclohexin standard liquid culture medium lacking histidine in a total volume imide [42] . All libraries encoded polypeptides fused to the carboxyl of 150 l, to which were added 1 l 0.5 mM IP-1-MFC and 1 l 0.4 terminus of the GAL4 activation domain. The total number of inde-mM MTX. To test for growth competition, either 1 l of DMSO pendent yeast colonies reflected at least 1ϫ the complexity of inde-(negative control, 100% growth) or 1 l of test MFC were added. pendent clones documented for the E. coli library, as specified by Yeast cell growth was monitored and quantified by measuring the the manufacturer. The yeast libraries were harvested, quality control optical density of the culture at day three at a wavelength of 600 nm. tested, and stored in small aliquots at Ϫ70ЊC.
A different reference MFC was used for IP-1 comparative analysis.
cDNA Library Screening Enzymatic Assays MFC (final concentration 4-8 M) was spread evenly onto screening
The appropriate kinases and cyclins were expressed in Sf9 insect Q-trays (Genetix, UK) with SD-agar lacking leu, trp, and his. A precells. CDK/cyclin complexes were purified and assayed as detransformed yeast library was applied onto the plates with a density scribed previously [28]. of approximately 5 ϫ 10 7 -1 ϫ 10 8 cells per tray. For a complex mammalian cDNA library screen, five Q-trays were screened. Even distribution of compound and yeast cells on the medium was en-Preparation of Cell Extracts cDNAs were cloned into pCMV-Tag3 vectors (Stratagene). Jurkat sured by distribution of the liquid with sterile 5 mm glass beads. Resulting colonies were transferred into 96-well flat bottom MTP's cells or 293 cells were propagated following standard protocols. 293 cells were transfected with pCMV-Tag3 vectors encoding myc-(Nunc, FRG) containing SD medium lacking leu and trp and containing 1 M betaine and incubated at 30ЊC for 3 days. For array tagged proteins using Effectene Transfection Reagent (QIAGEN, 301425). Cells were propagated for 40 hr under normal growth condi-specificity testing, a 20 l aliquot of yeast cells grown in a 96-well microtiter plate was spotted twice onto screening Q-trays using a tions. Whole-cell extracts were prepared following a protocol adapted from Romero et al. [38] and either stored at Ϫ80ЊC or used robotic liquid handling system (MultiPROBE II, Packard Bioscience). One microliter of compound of interest (5 mM or 0.5 mM stock directly for pull-down assays. Yeast extracts were generated by lysis of the cells with NaOH and 50% trichloroacetic acid. The pro-solutions) was spotted in the center of the cell spot. The trays were incubated for 2 days at 30ЊC, and compound-dependent growth teins were precipitated with ice-cold acetone and resuspended in sample buffer. was determined.
